AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06515782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.
Description: In one group investigators will look at the Med diet alone for 6 months. Then investigators will have the patients add on 3 rounds of FMD.~In the other group, patients will do Med diet and FMD for 6 months followed by Med diet alone for 6 months. This will allow investigators to look for a diminution in effect of the Med diet 6 months after the last FMD.
Study NCT04784689 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: COVID-19 Vaccine
Study NCT06027437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicamtiv
Description: Specified dose on specified days.
Study NCT05987384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arachidonic acid
Description: D3 ARA group will receive ARA capsules from the third day of the study. D6 ARA group will receive ARA capsules from the sixth day of the study
Study NCT05987384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Description: The placebo group and D6 ARA group will receive sunflower oil capsules from the third day of the study. D6 ARA group will stop receiving sunflower oil capsules from the fifth day of the study.
Study NCT05987384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil
Description: The placebo group and D6 ARA group will receive sunflower oil capsules from the third day of the study. D6 ARA group will stop receiving sunflower oil capsules from the fifth day of the study.
Study NCT05987384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine (Vero Cell) for Human Use
Description: Every participant will receive three doses of rabies vaccination.
Study NCT05987384 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies Vaccine (Vero Cell) for Human Use
Description: Every participant will receive three doses of rabies vaccination.
Study NCT06126198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS induces local electrical currents in the stimulated neurons and has been shown to induce long-term inhibition or excitation of groups of neurons in treated cortical areas
Study NCT06319833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity interacting with a video
Description: This experimental condition will be implemented five times a week, once per day, over 8 weeks. It will follow a structured format, including seven consecutive 40-second blocks of physical activity. The total video duration will amount to 9 minutes (40 seconds of activity followed by 20 seconds of rest, maintaining a 2:1 work-to-rest ratio). Additionally, participants will engage in 5 minutes of warm-up exercises and 5 minutes of cool-down activities. The experimental condition will consist of 10 videos, each centered around one of five different themes (a different one will be administered every day).
Study NCT04925440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum 1714® strain
Description: Probiotic capsules containing 5 x 10\^9 CFUs, corn-starch and magnesium stearate.
Study NCT04925440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing corn-starch and magnesium stearate only.
Study NCT01775098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: No arms will not be change as the study as been closed.
Study NCT01775098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: allopurinol
Description: No arms will not be change as the study as been closed.
Study NCT06290999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multifrequential admittancemetry
Description: Every participant of the study have to complete an Ear, Nose and Throat examination included a conventional audiometry, and a multifrequential admittancemetry.~if radio-interventional venous stenting is not indicated, an multifrequential admittancemetry will also be performed 3 months after the procedure.
Study NCT06524531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed RF Neuromodulation
Description: RF neuromodulation will be applied to the L2 and L3 segments bilaterally. Each segment will receive treatment for 6 minutes, either sequentially or simultaneously on both sides.
Study NCT06524531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte-Rich PRP Injection
Description: Leukocyte-rich PRP will be prepared from the patient's blood and injected into the multifidus muscle at the L2 and L3 levels.
Study NCT05915156 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Post-acute home physiotherapy program
Description: This health services research assessed the effects of a post-acute home physiotherapy program that was designed to provide physical rehabilitation services to older adults recently discharged from acute or post-acute care. Under this program, every patient was attended by a physiotherapy technologist within 48 hours of being discharged and received home physiotherapy for a minimum of three days per week for a maximum of eight weeks.
Study NCT06524531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy Alone
Description: Standard physiotherapy regimen tailored to each participant's needs. This may include exercises to improve flexibility, strength, and endurance of the back muscles, as well as education on posture and body mechanics.
Study NCT01481532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crotoxin
Description: Intra patient dose escalation
Study NCT05246267 — intervention group
Intervention type: BIOLOGICAL
Intervention: Dupilumab
Description: Standard of care treatment with dupilumab
Study NCT05355220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Spike Point Therapy (SSPT)
Description: Silver Spike Point Therapy (SSPT) means passing an electric current through the skin surface with the triangle spike silver coated metal electrode. SSPT was reported by Hyoto and Kitade in Edinburg, Scotland. 3rd World Congress on Pain in 1981; It has a number of advantages over traditional narcotic medication in pelvic girdle pain management. It does not depress the cardiovascular, respiratory, or the metabolic systems and has no apparent effect on the sensorium
Study NCT05355220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Managment
Description: 2 sets of 10 repetitions Bridging, Cat \& cow exercises, Back press exercises, stretching of hip external rotators and extensors 20 sec / stretch
Study NCT05533580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: The experimental group was sedated with remimazolam.
Study NCT05533580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The control group was sedated with propofol.
Study NCT05646849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connected application
Description: Recording and sharing sessions. Exchanges and interactions with other patients. Participation in three collective challenges.
Study NCT06244901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Exoskeleton
Description: Walking for twenty minutes with a wearable powered robotic ankle exoskeleton on real-world terrain every day for a week.
Study NCT06244901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal walking
Description: Normal walking for twenty minutes on real-world terrain every day for a week.
Study NCT06018103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-vision
Description: 8-week mindfulness group learning course, using Mindfulness Based Cognitive Therapy customised for visual symptoms (MBCT-vision). Participants meet once weekly only, with daily home practice between sessions.
Study NCT05571813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341
Description: A single dose of 1tablets under fasting condition
Study NCT05848063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global hip muscles strengthening exercises
Description: Strengthening exercises will be given to all hip muscles
Study NCT05848063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip abductors strengthening exercises
Description: Strengthening exercises will be given to hip abductor muscles
Study NCT05695287 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
Study NCT05695287 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isoflurane
Description: Isoflurane
Study NCT03883165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity neck strengthening
Description: All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting the chest, shoulders, back, upper and lower extremities, and core. Additionally, they will also perform a higher number of repetitions of manual resistance neck strengthening exercises in sagittal plane flexion and extension, coronal plane lateral flexion in both directions, and axial plane rotation in both directions,as well as dumbbell shoulder shrugs.
Study NCT03883165 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting only the chest, shoulders, back, upper and lower extremities, and core, without resistance exercises specifically targeting the neck.
Study NCT05695287 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Sevoflurane
Study NCT06339268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training, CogniFit App
Description: A patient will receive preoperative cognitive stimulation and physical therapy for one month before surgical treatment.
Study NCT04248283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Continence Therapy for Women (ACT)
Description: Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).
Study NCT06409156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oblique Subcostal Transversus Abdominis Plane Block
Description: With the OSTAP block, local anesthetic is injected into the fascial plane between the posterior rectus sheath and the transversus abdominis muscle beneath the subcostal margin.
Study NCT06409156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Oblique Intercostal Fascial Plane block
Description: With the EOIF block, local anesthetic targets the terminal part of the thoracoabdominal nerves pass behind the costal cartilage and continue anteriorly in the plane between the internal oblique and transversus abdominis muscle, before piercing the rectus abdominis sheath as anterior cutaneous branches supplying the skin of the midabdomen.
Study NCT05254977 — intervention group
Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects
Study NCT06372132 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: G-POEM
Description: Gastric Per-Oral Endoscopic Pyloromyotomy
Study NCT06372132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: G-POEM
Description: Gastric Per-Oral Endoscopic Pyloromyotomy
Study NCT05397990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks of moderate intensity exercise, three times a week.
Study NCT06269445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin Combined With Bevacizumab and FOLFIRI
Description: Bevacizumab and FOLFIRI are second-line treatment options for colorectal cancer; synergistic efficacy expected in combination with Icaritin
Study NCT05558540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord stimulator
Description: By continuous electrical stimulation of the nerve causing endometriosis-related pain, painful inputs to the spinal cord and brain can be reduced or even eliminated. The electrical stimulation is performed by the spinal cord stimulator (SCS).
Study NCT05192447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Description: Patients selected to EG will carry out complementary cognitive and physical training under supervision of rehabilitation staff. For neuropsychological exercises, the investigators will use the RehaCom system - high quality scientific neurocognitive disorder therapy programs and software. (Time: 30 min./5 times/week per patient during RT). In this time, EG patients will do physical training (such as cycling, running on properly calibrated equipment for the circulatory system parameter measurement (1hour/ 5 days/ week), and neuromuscular and cognitive reeducation exercises using a technically advanced tool - Neuroforma computer software - 30 min/ 5 times/ week). After the end of RT, patients in EG will do a special exercise training at home under supervision of staff from the Department of Rehabilitation, and cognitive training using special tasks (3 times an hour/per week) at home, and two times/week using RehaCom and Neuroforma (60 min/sesion) in our cancer ceter.
Study NCT05858424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary day hospitalization
Description: This multidisciplinary day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. The objectives of this medical interview, conducted by a clinician researcher, are to summarize the pathology, the treatment(s) received, and to develop a personalized after-cancer plan.~The psychological interview will assess the needs for further care, and will refer the former patient if necessary.~The social interview will take stock of the former patient's return to school and/or professional life, and direct him/her to possible applications for social assistance if needed.~If needs of supportive care emerge from the history of treatment period, some consultations can be added during the day hospitalization, like an interview with a dietician or an adapted physical activity assessment.
Study NCT05726253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care + Amoxicillin
Description: Participants will be randomized to receive oral amoxicillin for a standard course (7 days)
Study NCT05726253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Care + Placebo (no antibiotics)
Description: Participants will be randomized to receive oral placebo for a standard course (7 days)
Study NCT05053490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: Static stretches are those in which you stand, sit or lie still and hold a single position for a period of time.
Study NCT05053490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic stretching
Description: Dynamic stretching involves making active movements that stretch the muscles to their full range of motion.
Study NCT05380401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Enfamil® DHA & ARA Supplement for Special Dietary Use
Description: Dosage: 60 mg/kg/day of DHA and 120 mg/kg/day of ARA. Route of administration: enteral tube or by oral syringe
Study NCT04742699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant (LEM) 5 mg (Z-Drug-mono cohort)
Description: 1. Pretreatment phase: Continue pre-registration treatment (Z-drug monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for Z-Drug. Increasing LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment from the first treatment phase. Changing LEM dose is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition.
Study NCT04742699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant (LEM) 5 mg (SUV-mono cohort)
Description: 1. Pretreatment phase: Continue pre-registration treatment (SUV monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed.
Study NCT04742699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant (LEM) 5 mg (SUV-combination cohort)
Description: 1. Pretreatment phase: Continue pre-registration treatment (SUV and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition.
Study NCT04742699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant (LEM) 5 mg (RMT-combination cohort)
Description: 1. Pretreatment phase: Continue pre-registration treatment (RMT and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for RMT and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition.
Study NCT04814797 — intervention group
Intervention type: OTHER
Intervention: Capnography data included in Lung Clearance Index measurement
Description: Capnography data included in Lung Clearance Index measurement (a pulmonary function test included in routinely yearly follow-up of cystic fibrosis children) will be collected and analyzed
Study NCT05078762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality
Description: Training in an iVR environment with Virtual Reality Goggles while using the bronchoscopy simulator, while the control group will train without VR goggles.
Study NCT06396104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilisation with movement
Description: The physiotherapist places the medial edge of the thumb of one hand on the upper facet joint of the relevant segment, then applies superior-anterior slide to the facet joint by providing support with the thumb of the other hand. The 'gliding' movement is maintained while the patient actively performs the unilateral neck rotation movement and maintains it for a few seconds at the end of the movement. If joint movement is painful, attempts are made on the other facet joint of the same segment or on the spinous process. If this attempt does not immediately improve the patient's active joint motion, Mulligan Sustained Natural Apophyseal Glides (SNAG) will be applied to the upper part of the left zygapophysial joint, and in case of failure again, application will be made through the superior spinous process of the relevant segment. Painless joint movement will be applied in 6 repetitions and 3 sets.
Study NCT06396104 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham mobilisation
Description: While the patients are sitting in a chair with a supported back, the spinal segment where pain is felt in neck joint movements will be determined. Without applying a sliding movement to this segment over the facet joint, only sensory input will be given and the patient will be asked to continue the active rotation movement and wait a few seconds at the end of the movement. The application will be completed as 6 repetitions and 3 sets.
Study NCT05700864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenegermin-Bkbj
Description: Cenegermin-bkbj ophthalmic solution administered as one drop in both eyes every 3 hours 4 times daily for 4 weeks
Study NCT05686941 — intervention group
Intervention type: OTHER
Intervention: Trans-cutaneous Laryngeal ultrasound (TLUS)
Description: Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords
Study NCT05686941 — intervention group
Intervention type: OTHER
Intervention: TLUS and simultaneous laryngoscopy
Description: Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords with simultaneous video laryngoscopy (usual care)
Study NCT06087861 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: Radiation will be delivered by external beam techniques to the tumor and areas of possible microscopic disease at a dose of 30 Gy divided into 5 equal fractions of 6 Gy (administered over a total of 5 to 10 business day
Study NCT05507112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy
Study NCT05507112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.
Study NCT05507112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.